Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia

被引:22
作者
Wigg, Alan J. [1 ,2 ]
Narayana, Sumudu K. [1 ,2 ]
Hartel, Gunter [3 ]
Medlin, Linda [4 ]
Pratt, Greg [3 ]
Powell, Elizabeth E. [5 ,6 ]
Clark, Paul [7 ]
Davies, Jane [8 ,9 ]
Campbell, Kirsty [9 ]
Toombs, Maree [10 ]
Larkin, Michael [11 ]
Valery, Patricia C. [3 ]
机构
[1] Southern Adelaide Local Hlth Network, Hepatol & Liver Transplant Med Unit, Adelaide, SA, Australia
[2] Flinders Univ South Australia, Adelaide, SA, Australia
[3] QIMR Berghofer Med Res Inst, Herston, Qld, Australia
[4] Cent Queensland Hosp & Hlth Serv, Aboriginal & Torres Strait Islander Hlth & Wellbe, Longreach, Qld, Australia
[5] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia
[6] Univ Queensland, Fac Med, Ctr Liver Dis Res, Translat Res Inst, Brisbane, Qld, Australia
[7] Mater Hosp, Brisbane, Qld, Australia
[8] Royal Darwin Hosp, Menzies Sch Hlth Res, Darwin, NT, Australia
[9] Royal Darwin Hosp, Darwin, NT, Australia
[10] Univ Queensland, Herston, Qld, Australia
[11] Aboriginal Hlth Council South Australia, Adelaide, SA, Australia
关键词
Liver cancer; Survival; Indigenous Australians; Epidemiology;
D O I
10.1016/j.eclinm.2021.100919
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver disease and hepatocellular carcinoma (HCC) are important contributors to the mortality gap between Indigenous and non-Indigenous Australians. However, there is a lack of population based high quality data assessing the differences in HCC epidemiology and outcomes according to Indigenous status. The aim of this study was therefore to perform a large epidemiological study of HCC investigating differences between Indigenous and non-Indigenous Australians with HCC. Methods: Study design was a retrospective cohort study. Data linkage methodology was used to link data from cancer registries with hospital separation summaries across three Australian jurisdictions during 2000-2017. Cumulative survival (Kaplan-Meier) and the differences in survival (Multivariable Cox-regression) by Indigenous status were assessed. Findings: A total of 229 Indigenous and 3587 non-Indigenous HCC cases were included in the analyses. Significant epidemiological differences identified for Indigenous HCC cases included younger age at onset, higher proportion of females, higher rurality, lower socioeconomic status, and higher comorbidity burden (all p < 0.001). The distribution of cofactors was also significantly different for Indigenous Australians including higher prevalence of alcohol misuse, hepatitis B, and diabetes and more frequent presence of multiple HCC cofactors (all p < 0.001). Indigenous Australians received curative HCC therapies less frequently (6.6% vs. 14.5%, p < 0.001) and had poorer 5-year survival (10.0% vs. 17.3%, p < 0.001; unadjusted hazard ratio (HR) =1.42 96%CI 1.21-1.65) compared to non-Indigenous Australians. The strength of the association between indigenous status and survival was weaker and statistically non-significant after adjusting for rurality, comorbidity burden and lack of curative therapy (adjusted-HR=1.20 95%CI 0.97-1.47) Interpretation: Such data provide a call to action to help design and implement health literacy, liver management and HCC surveillance programs for Indigenous people to help close the liver cancer mortality gap. (C) 2021 Published by Elsevier Ltd.
引用
收藏
页数:9
相关论文
共 20 条
[1]  
[Anonymous], 2017, NATL REPORT
[2]  
[Anonymous], 2008, CENS POP HOUS SOC EC
[3]  
[Anonymous], 2018, Leading causes of death and numbers of deaths, by age: United States, 1980 and 2017
[4]  
[Anonymous], VIRAL HEPATITIS MAPP
[5]  
Australian Institute of Health and Welfare, 2010, CONTR CHRON DIS HAP
[6]  
Australian Institute of Health and Welfare, 2018, CANC AB TORR STRAIT
[7]  
Australian Institute of Health and Welfare (AIHW), 2004, RUR REG REM HLTH GUI
[8]  
Australian Institute of Health and Welfare Cancer in australia, 2017, CAN SER, V101
[9]   A NEW ANTIGEN IN LEUKEMIA SERA [J].
BLUMBERG, BS ;
ALTER, HJ ;
VISNICH, S .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 191 (07) :541-&
[10]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022